Navigation Links
K-V Pharmaceutical Company Announces the Completion of the Sale of Nesher Pharmaceuticals, Inc. its Generic Pharmaceutical Business
Date:8/8/2011

ed to) the following:

(1) the Company's ability to continue as a going concern;

(2) compliance by the Company and the Buyer with their respective related contractual obligations under the definitive Asset Purchase Agreement, dated June 17, 2011 for the sale of Nesher assets, the Company's generic products business and Nesher subsidiary;  

(3) the impact of competitive, commercial, payor, governmental (including Medicaid program), physician, patient, public or political responses and reactions, and responses and reactions by medical professional associations and advocacy groups, to the Company's sales, marketing, product pricing, product access and strategic efforts with respect to Makena™, (hydroxyprogesterone caproate injection), and its other products, including introduction or potential introduction of generic or competing products, or competition from unapproved therapies or compounded drugs, against products sold by the Company and its subsidiaries, including Makena™, and including competitive or responsive pricing changes;

(4) the impact of: (i) the U.S. Food and Drug Administration (FDA) decision to decline to take enforcement action with regards to compounded alternatives to Makena™, despite the Company's orphan drug exclusivity; (ii) CMS policy permitting Medicaid program reimbursement of such products; and (iii) resulting coverage decisions by various state Medicaid and commercial payors, on the Company's sales revenues for Makena™ and the resulting impact on the Company's operations and financial results, including, without limitation, its ability to continue as a going concern;

(5) new product development and launch, including the possibility that any product launch may be delayed or unsuccessful, including with respect to Makena™;

(6) acceptance of and demand for the Company's new pharmaceutical products, including Makena™, and
'/>"/>

SOURCE K-V Pharmaceutical Company
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
7. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
8. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
9. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
10. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
11. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)...  Sanofi (EURONEXT: SAN and NYSE: SNY ) ... , examining the selective JAK2 inhibitor SAR302503 for ... groups. The primary endpoint assessed the proportion of patients ... reported in previous trials, the most common adverse events ... be presented at an upcoming medical congress. ...
(Date:5/16/2013)... ZURICH , May 17, 2013 ... Research (A*STAR) and Switzerland,s Cytos Biotechnology ... dosed in a Phase 1 clinical trial with their H1N1 ... particle (VLP) technology. In this first Phase 1 clinical trial, ... its potential to protect against H1N1 influenza infection will be ...
(Date:5/16/2013)... N.C. , May 16, 2013  Today, the ... North Carolina House of Representatives recently approved ... for chemotherapy from charging patients higher out-of-pocket fees for ... formularies, many of which have more severe side-effects. However, ... limit of $300, which will continue to be a ...
Breaking Medicine Technology:Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 2Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 3Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 4Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 5Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 6A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 2A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 3A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 4A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 5A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 6National Patient Advocate Foundation Responds to N.C. State House Approval of Flawed Cancer Treatment Fairness Bill 2National Patient Advocate Foundation Responds to N.C. State House Approval of Flawed Cancer Treatment Fairness Bill 3
... III study will evaluate effects of otelixizumab, an investigational anti-CD3 ... ... secretion, CAMBRIDGE, Mass., April 9, 2008 ... development of novel,therapies for immune-mediated diseases, today announced that it is,proceeding ...
... Calif., April 9, 2008 ,Poniard Pharmaceuticals, Inc. (Nasdaq: ... today announced that data from a Phase 2 ... patients with small,cell lung cancer (SCLC) will be ... Lung Cancer Conference in Geneva, Switzerland. The presentation ...
Cached Medicine Technology:Tolerx Advancing Novel Type 1 Diabetes Agent into Phase III Clinical Trial Program Following End of Phase II FDA Meeting 2Tolerx Advancing Novel Type 1 Diabetes Agent into Phase III Clinical Trial Program Following End of Phase II FDA Meeting 3Tolerx Advancing Novel Type 1 Diabetes Agent into Phase III Clinical Trial Program Following End of Phase II FDA Meeting 4Poniard Pharmaceuticals Announces Presentation of Clinical Data From Picoplatin Phase 2 Small Cell Lung Cancer Trial to be Presented at 1st IASLC-ESMO European Lung Cancer Conference 2Poniard Pharmaceuticals Announces Presentation of Clinical Data From Picoplatin Phase 2 Small Cell Lung Cancer Trial to be Presented at 1st IASLC-ESMO European Lung Cancer Conference 3
(Date:5/19/2013)... Omaha, Nebraska is a city of diversity, economic ... of the lowest unemployment rates in the country. Forbes Magazine ... for Business and Careers and it consistently scores high on ... located in the nation and is a strong business leader ... of Editions TV are pleased to announce air ...
(Date:5/19/2013)... Chicago, IL (PRWEB) May 19, 2013 In ... Surge, LLC, E-dentist.com has announced the launch of an SEO ... help dentists get high rankings in Google. , http://www.e-dentists.com/ ... do not pay for the service until they see results. ... sites. The lead generation websites run by JD Media Surge, ...
(Date:5/19/2013)... The muscles in the human body ... one of the biggest and most significant nervous systems ... peripheral system comprises of peripheral nerves that reside outside ... ensure that the limbs and hands, as well as ... get damaged due to trauma or physical injury, their ...
(Date:5/19/2013)... California (PRWEB) May 19, 2013 Grinding ... than just losing sleep, or annoying your spouse. At ... report by CNY Central (“Snoring and Teeth Grinding Could ... type of teeth grinding can be hard to prevent. ... million Americans, and one of its symptoms is a ...
(Date:5/19/2013)... 6Webs.com is the leader in reviews ... are considering an alarm system can do a comparison ... security system providers online at 6Webs.com. Just recently finishing ... home security system companies, 6Webs.com currently is announcing ... home security companies before ranking the home security system ...
Breaking Medicine News(10 mins):Health News:Editions TV Announces May Air Dates for Omaha, Nebraska 2Health News:Effective New Dental SEO Solution Launched by E-dentists.com in Partnership with JD Media Surge, LLC 2Health News:Ultimate Neuropathy Support System Launched by Neuracel - Reaching New Heights in Herbal Medication for Peripheral Neuropathy 2Health News:Dr. Kanani, Woodland Hills Dentist: Dangers of Tooth Damage and Obstructive Sleep Disorder 2Health News:Dr. Kanani, Woodland Hills Dentist: Dangers of Tooth Damage and Obstructive Sleep Disorder 3Health News:Top Rated DIY Home Security System Companies Published by 6Webs.com 2
... possible relation between acne and milk. Dermatologists at ... culprit is Iodine. ,Teenagers being plagued with acne can ... out. Previously thought to be hormones or “bioactive chemicals” ... is credited with the finding. , ,"It has been ...
... auditory and visual aspects of speech can be processed much ... hearing impairment, if the cochlear implant is carried out at ... implants. About 36 profoundly deaf children aged between 5 years ... had received the cochlear implant for a period of one ...
... assess the effectiveness of the federal government’s plans to ... the United States, the White House is hosting a ... for four hours and would be attended by Cabinet ... President however would be excluded from the top-level meeting, ...
... In a new, unique study conducted on babies and birth ... birth weight display an increased liking for salt.// The results ... individuals include more salt in their diet than others. ... atleast 2.5 kg. These babies were given both plain and ...
... are obese before pregnancy or who smoke during pregnancy, have ... age//. ,The researchers also say the condition ... research paper published in the journal Pediatrics. ... Ohio State University, Columbus, who were interested in how pre-pregnancy ...
... study conducted and headed by Veronique Roger, M.D., M.P.H., at ... is a high risk of these patients suffering from stroke//. ... was 44 times more during the 30 day period after ... person. ,The study is very important because with today’s ...
Cached Medicine News:Health News:Early Cochlear Implants Prove To Be Effective 2Health News:Birth Weight of Babies Important Predictor for Salt Preference 2Health News:Kids of overweight mothers have higher obesity risk 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: